Infection  >>  SQ-109  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SQ-109 / Sequella
SQ109EBA, NCT01218217: Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB

Completed
2a
90
RoW
SQ109, Rifampicin
Michael Hoelscher, Sequella, Inc., European and Developing Countries Clinical Trials Partnership (EDCTP), German Federal Ministry of Education and Research, Quintiles, Inc., CMed Technologies Inc., PathCare, Parexel
Tuberculosis, Pulmonary
09/11
05/12
NCT01252108: Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers

Withdrawn
2a
0
US
SQ109
Sequella, Inc.
Helicobacter Pylori Infection
08/15
08/15
NCT01785186: Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Completed
2
365
RoW
SQ109, Rifampicin, Moxifloxacin, isoniazid, pyrazinamide, ethambutol, pyridoxine
Michael Hoelscher, Sequella, Inc., European and Developing Countries Clinical Trials Partnership (EDCTP), German Federal Ministry of Education and Research, Medical Research Council, Radboud University Medical Center
Tuberculosis, Pulmonary
09/14
03/15

Download Options